The underlying science is published and peer-reviewed. The platform built on it is ours, and most of it is not on this page.
Proteins do the work in a cell, and most disease drivers are proteins. Every drug that acts on one depends on a structural feature the hardest targets do not have. When the target has none of them, there is no modality. That is not a gap in anyone's pipeline. It is a gap in the toolkit.
The answer is not a better drug for a protein. It is the ability to edit the protein itself.
We edit proteins directly, in living cells, in the form they already exist in. Cut one and it stops working, or loses a piece it should not have, or separates into the two halves it was built from. Join two and something exists that did not before. Do both at once and the sequence itself is rewritten. No prior engineering of the target. No permanent change to the genome.
Switch a protein off, shorten it, or separate what should not be joined.
Install something new, or connect two pieces into one.
Remove a segment and put another in its place. What results is not the protein that was there.
Edits are not written into the genome. They resolve on their own, which makes the intervention tunable rather than permanent.
Designing an editor for a new protein used to be a bespoke campaign. The engine replaces it. A target protein goes in. Candidates are designed and screened computationally, long before anything is built, and only what survives reaches the bench.
Then the loop closes. What the lab measures goes back into the models. Every target run makes the next one faster and the one after that cheaper. This is what separates a platform from a project, and it is the part that compounds.
Candidates designed and screened before anything is built.
Only what survives the screen reaches the bench.
Every result retrains the models. The cycle gets shorter each time.
Therapeutics are where this goes first and where it matters most, with other uses of the same platform downstream of that. One system, pointed at a new protein rather than rebuilt for it.
Genomes became programmable. Proteins did not. This is the layer no one built.
Every capability added applies to every protein already in reach.
Every target run makes the next one faster. Nothing about that resets.
We are deliberately light on detail here. If you work in therapeutics, protein engineering, or you invest in platforms early, the full picture is a conversation away.
Start a conversation